Galapagos NV is abandoning its small molecule roots to focus on cell therapy and at the same time splitting in two, with the spinout company, dedicated to acquiring a portfolio of assets, taking the ...

the Royalty Agreement, under which Galapagos will gain full global development and commercialization rights to its pipeline, subject to payment of single digit royalties to Gilead on net sales of ...

Gilead Sciences (GILD) partners with LEO Pharma in a $1.7B agreement to develop anti-inflammatory drugs. Read more here.

By mid-2025, the biotech will split into two entities: a new, as-yet-unnamed innovative medicines specialist and a cell ...

The key Ulcerative Colitis therapies expected to launch in the market include Jyseleca (filgotinib), Rinvoq (Upadacitinib), ...

Leerink Partners analyst Faisal Khurshid has maintained their neutral stance on GLPG stock, giving a Hold rating on December 23.Stay Ahead of ...

Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its ...

Bank of America Securities analyst Jason Gerberry maintained a Sell rating on Galapagos (GLPG – Research Report) today and set a price target ...

The changes will result in one company focused exclusively on cancer cell therapies and another on strategic transactions to build a pipeline of innovative medicines.

Galapagos will gain full development and commercialization rights to its pipeline, and is subject to single digit royalty ...

Galapagos NV plans to split into two entities by mid-2025, focusing on oncology cell therapy and innovative medicines, with ...

U.S.-listed shares rose over 4% in Wednesday's premarket after it announced a significant restructuring plan, including a ...